Early Life
Julian Baker's career in finance began after graduating magna cum laude from Harvard University. He honed his skills in the private equity investment arm of Credit Suisse First Boston Corporation from 1988 to 1993. This experience provided a foundation for his future endeavors in the biotech sector.
Rise to Success
In 1994, Baker began managing healthcare investments for the Laurence Tisch family, which owned the Loews Corporation. This early experience laid the groundwork for his later venture. In 2000, he co-founded Baker Bros. Advisors with his brother Felix Baker. The firm quickly gained recognition as a leading biotechnology investor, managing assets of approximately $18 billion as of March 2025. Julian Baker's strategy focuses on concentrated, long-term investments in promising biotechnology and life sciences companies, often taking an active role in supporting portfolio companies.
Key Business Strategies
Baker Bros. Advisors employs a fundamentally driven approach to life sciences investing, focusing on publicly traded biotechnology and life sciences companies. The firm's strategy involves detailed scientific and financial due diligence, which frequently leads to substantial position concentrations. Notably, the firm held a significant stake in Seagen (formerly Seattle Genetics), which resulted in a large return when Pfizer acquired the company in 2023. Julian Baker also serves as Chairman of the Board for multiple publicly traded companies, including Incyte Corporation.
Philanthropy
Julian Baker, along with his brother, established the J Baker Foundation Inc. in 2013. This foundation supports various organizations through monetary grants, donations, and educational support. The foundation’s giving reflects their interests in higher education, healthcare innovation, food security, and educational institutions.
